<DOC>
	<DOCNO>NCT00787969</DOCNO>
	<brief_summary>This phase I/II trial study side effect best dose temsirolimus give together cladribine rituximab see well work treat patient newly diagnose mantle cell lymphoma . Monoclonal antibody , rituximab , may interfere ability cancer cell grow spread . Drugs use chemotherapy , cladribine , work different way stop growth cancer cell , either kill cell , stop dividing , stop spread . Temsirolimus may stop growth cancer cell block enzymes need cell growth . Giving temsirolimus together cladribine rituximab may kill cancer cell .</brief_summary>
	<brief_title>Rituximab , Cladribine , Temsirolimus Treating Patients With Newly Diagnosed Mantle Cell Lymphoma</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To assess efficacy safety combination rituximab , cladribine , temsirolimus newly diagnose mantle cell lymphoma . II . To determine maximum tolerate dose ( MTD ) temsirolimus combine fix dose schedule rituximab cladribine . ( Phase I ) III . To assess efficacy combination rituximab , cladribine , temsirolimus newly diagnose mantle cell lymphoma proportion complete response primary endpoint . ( Phase II ) SECONDARY OBJECTIVES : I . To assess measure efficacy regimen include progression free survival , duration response , overall survival . II . To assess toxicity profile combination rituximab , cladribine , temsirolimus . III . To assess efficacy use traditional lymphoma parameter absolute lymphocyte count . IV . To assess metabolic marker ( hyperglycemia , hyperlipidemia ) marker mammalian target rapamycin ( mTOR ) inhibition use glucose lipid measurement perform clinical laboratory part routine care . V. To correlate response serum free light chain , single nucleotide polymorphism ( SNPs ) host immune gene , vitamin D metabolites , phosphatidylinositide 3-kinase ( PI3K ) pathway member expression . VI . As part ongoing research North Central Cancer Treatment Group ( NCCTG ) lymphoma study , paraffin-embedded tissue blocks/slides blood product bank future study . OUTLINE : This phase I , dose-escalation study temsirolimus follow phase II study . Patients receive rituximab intravenously ( IV ) day 1 cladribine IV 2 hour day 1-5 . Patients receive temsirolimus IV 30 minute day 1 , 8 , 15 , 22 . Patients also receive filgrastim subcutaneously ( SC ) day 6-15 pegfilgrastim SC day 6 . Treatment repeat every 28 day 6 course absence disease progression unacceptable toxicity . After completion study treatment , patient follow every 3 month 2 year every 4 month 3 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Cladribine</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>Histologically confirm mantle cell lymphoma ( MCL ) ; diagnosis must confirm NCCTG preregistration pathology review Dr. Paul Kurtin designate ; recommend biopsy excisional biopsy , adequate coreneedle biopsy accept long consider adequate registration Dr. Kurtin designate ; tumor must cyclin D1 positive immunohistochemistry evidence ( 11 ; 14 ) translocation fluorescence base situ hybridization ( FISH ) cytogenetics Measurable assessable disease , define least one following : A lymph node tumor mass &gt; = 2.0 cm least one dimension positron emission tomography ( PET ) /computed tomography ( CT ) , CT , magnetic resonance imaging ( MRI ) , plain radiograph image Splenic enlargement may use measurable parameter spleen palpable &gt; = 3 cm leave costal margin Diffuse infiltration organ stomach , bone marrow , peripheral blood , liver , lung , bowel lymphoma without discrete mass would constitute assessable , measurable , disease Eastern Cooperative Oncology Group ( ECOG ) performance status ( PS ) 0 , 1 , 2 , 3 Life expectancy &gt; = 12 week Absolute neutrophil count ( ANC ) &gt; = 1,500/mm³ Platelet count ( PLT ) &gt; = 100,000/mm³ Serum creatinine = &lt; 2.0 mg/dL Serum total bilirubin ( direct bilirubin total abnormal ) = &lt; institutional upper limit normal ( ULN ) without secondary liver involvement Serum glutamic oxaloacetic transaminase ( SGOT ) = &lt; 3 x institutional ULN ( exception : liver involvement , SGOT must = &lt; 5 x institutional ULN ) Negative pregnancy test do = &lt; 7 day prior registration , woman childbearing potential Willingness return NCCTG enrol institution followup Willingness provide blood specimen require protocol Willingness provide tissue specimen require protocol Willing return NCCTG enrol institution followup Willing provide blood tissue specimen require protocol Willing abstain eat grapefruit drinking grapefruit juice Willingness abstain eat grapefruit drinking grapefruit juice duration study Exclusion Criteria Any prior therapy mantle cell nonHodgkin lymphoma include radiation therapy ; exception : patient may undergo splenectomy diagnosis , cytopenia , systematic splenomegaly Active uncontrolled infection Any follow cardiac condition : Uncontrolled high blood pressure Unstable angina Active congestive heart failure Myocardial infarction = &lt; 6 month Serious uncontrolled cardiac arrhythmia Known central nervous system ( CNS ) involvement Any following : Pregnant woman woman reproductive ability unwilling use effective contraception take drug 12 month stop treatment Nursing woman Men unwilling use condom ( even undergone prior vasectomy ) intercourse woman , take drug 12 month stop treatment Medical psychiatric condition , opinion investigator , make patient poor risk participation Known human immunodeficiency virus ( HIV ) positive ; HIV testing require do clinically indicate ; HIVpositive patient receive combination antiretroviral therapy exclude study Concurrent malignancy = &lt; 5 year ago ; exception : carcinoma situ cervix , resect basal cell squamous cell carcinoma skin , prostate cancer remission follow radical retropubic prostatectomy radiation therapy ; history prior malignancy , must receive specific treatment ( hormonal therapy ) cancer Known hypersensitivity rituximab component , murine protein Receiving investigational agent would consider treatment primary neoplasm Prior treatment mTOR inhibitor Autologous allogeneic stem cell transplant plan part initial therapy Receiving enzymeinducing antiepileptic drug ( enzyme induce antiepileptic drug [ EIAEDs ] ; e.g. , phenytoin , fosphenytoin , carbamazepine , oxcarbazepine , phenobarbital , primidone ) ; potent cytochrome P450 , family 3 , subfamily A , polypeptide 4 ( CYP3A4 ) inducer rifampin , glucocorticoid great adrenal replacement level , St. John 's wort ; receive strong CYP3A4 inhibitor * Note : agent discontinue , temsirolimus therapy begin &gt; = 7 day discontinuation agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>stage I mantle cell lymphoma</keyword>
	<keyword>Stage II Contiguous Mantle Cell Lymphoma</keyword>
	<keyword>Stage II Non-Contiguous Mantle Cell Lymphoma</keyword>
	<keyword>Stage III Mantle Cell Lymphoma</keyword>
	<keyword>Stage IV Mantle Cell Lymphoma</keyword>
</DOC>